Optimizing Management of HR+/HER2- BC: Future Directions in Care
Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.
Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition
Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.
Considerations for Use of ADCs in HER2-Low Breast Cancer
A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.
ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04
Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.
Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer
Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.
Novel Therapy for Relapsed/Refractory HR+ BC: PI3K Inhibitors
Expert perspectives on the current paradigm of PI3K inhibition in the setting of relapsed/refractory HR+/HER2- breast cancer.
Novel Therapy for Relapsed/Refractory HR+ BC: Oral SERDs
A brief overview of oral SERDs currently being investigated in the setting of relapsed/refractory HR+/HER2- breast cancer.
HR+ BC: Is There Still a Role for Everolimus Post–Endocrine Therapy?
Panelists briefly consider the ongoing role of everolimus in relapsed/refractory HR+/HER2- breast cancer given recent shifts in the treatment paradigm.
Novel Treatment Approaches to Relapsed/Refractory HR+ Breast Cancer
Comprehensive insight on novel treatment approaches in the setting of relapsed/refractory HR+/HER2- breast cancer, including oral SERDs, SERMs, and ER PROTAC degraders.
Is There a Role for CDK4/6 Inhibition in HR+/HER2+ Breast Cancer?
Shifting their focus to the HR+/HER2+ setting of breast cancer, expert panelists consider the potential of CDK4/6 inhibition in light of clinical trial data.
Frontline Combination Strategies in HR+/HER2- BC
A brief review of frontline combination strategies in the context of multiple driver pathways in HR+/HER2- breast cancer.
Real-World Use of CDK4/6 Inhibition in HR+/HER2- Breast Cancer
Experts home in on real-world data and resistance mechanisms to discuss practical use of CDK4/6 inhibition in HR+/HER2- breast cancer.v
HR+/HER2- Breast Cancer: Identifying Barriers to Use of CDK4/6 Inhibition
Comprehensive insight on the barriers to CDK4/6 inhibition in HR+/HER2- breast cancer, from both medical and accessibility perspectives.
HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting
Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib
Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.
CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib
Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.
Frontline Treatment Strategies for HR+/HER2- Breast Cancer
Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.
SABCS 2021: Novel Approaches to Breast Cancer Management
After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.
SABCS 2021: Brain Metastases Updates in Breast Cancer
Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.
SABCS 2021: Updates in Metastatic Breast Cancer
Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512